Engineered immune cells take on tough blood cancers
NCT ID NCT03050190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety and how well the cells work in up to 200 participants aged 6 months and older.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
- Double-Pronged immune cells take aim at blood cancers
- Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
- Off-the-Shelf CAR t cells take on tough blood cancers
- Hidden danger: why some patients can't shake COVID-19
- New drug HRS-1635 enters early human testing for hard-to-treat blood cancers